The purpose of this proposal is to investigate the cell biological and molecular pathways that regulate platelet production. Although it is well established that megakaryocytes generate platelets by remodeling their cytoplasm into proplatelet extensions, which serve as assembly lines for platelet production, many unanswered questions remain regarding the mechanisms of platelet biogenesis. In particular, our understanding of the process by which megakaryocytes initiate proplatelet production is poorly understood. We have recently used a novel microinjection approach to discover a cytoplasmic factor, called proplatelet-promoting factor (PPF) that triggers platelet production when injected into megakaryocytes. Even though our preliminary data have clarified some questions about the basic nature of PPF activity, we only have a cursory understanding of its regulation and mechanism of action. Obtaining this fundamental knowledge is crucial for evaluating the scope of PPF action and determining how it functions in proplatelet initiation. Therefore, in Specific Aim 1 we propose to define the biological nature of PPF activity and isolate PPF so that we can understand how this cytoplasmic factor controls proplatelet induction. Although the mechanism by which the cytoskeleton regulates proplatelet initiation is unknown, the spatial and temporal disassembly of the centrosome after the injection of PPF, but before proplatelet initiation, suggests a role for the centrosome in proplatelet induction. This exciting new data suggests that centrosome disassembly powers induction of proplatelet production, a hypothesis that will be tested in Specific Aim 2. Finally, in Specific Aim 3 we will use a high-content microscopy screen to identify molecules that drive platelet production. Using proplatelet image analysis, we will test thousands of drug molecule candidates for their ability to stimulate or inhibit platelet production. Target pathway analysis, secondary screens, and dose-response curves will be used to identify compound ?hits.? We will then establish whether hits are efficacious in animal models. Taken together, we expect that findings made as a result of this investigation will provide an improved understanding of the molecular mechanisms that regulate platelet formation and lay the foundation for novel therapeutic approaches to accelerate platelet production in patients with thrombocytopenia.

Public Health Relevance

Blood platelets play a critical role in stimulating clot formation and repair of vascular injury. Life-threatening thrombocytopenia (low platelet count) can occur in patients for a variety of reasons, including chemotherapy, radiation treatment, trauma, severe burns, organ transplant surgery, and genetic disorders. The studies proposed in this application will advance our understanding of blood platelet production and may lead to improved therapies for accelerating platelet production in these patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL068130-19
Application #
9912219
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Sarkar, Rita
Project Start
2001-07-01
Project End
2021-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
19
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Noetzli, Leila J; Italiano Jr, Joseph E (2018) Unlocking the Molecular Secrete(s) of ?-Granule Biogenesis. Arterioscler Thromb Vasc Biol 38:2539-2541
Paul, David S; Casari, Caterina; Wu, Congying et al. (2017) Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice. Blood Adv 1:1398-1408
Machlus, Kellie R; Wu, Stephen K; Vijey, Prakrith et al. (2017) Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood 130:1132-1143
Kim, Kyungho; Tseng, Alan; Barazia, Andrew et al. (2017) DREAM plays an important role in platelet activation and thrombogenesis. Blood 129:209-225
Cunin, Pierre; Penke, Loka R; Thon, Jonathan N et al. (2017) Megakaryocytes compensate for Kit insufficiency in murine arthritis. J Clin Invest 127:1714-1724
Johnson, Kelly E; Forward, Jodi A; Tippy, Mason D et al. (2017) Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis. Arterioscler Thromb Vasc Biol 37:664-674
Zufferey, Anne; Speck, Edwin R; Machlus, Kellie R et al. (2017) Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets. Blood Adv 1:1773-1785
Machlus, Kellie R; Johnson, Kelly E; Kulenthirarajan, Rajesh et al. (2016) CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood 127:921-6
Machlus, Kellie R; Wu, Stephen K; Stumpo, Deborah J et al. (2016) Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation. Blood 127:1468-80
Bender, Markus; Thon, Jonathan N; Ehrlicher, Allen J et al. (2015) Microtubule sliding drives proplatelet elongation and is dependent on cytoplasmic dynein. Blood 125:860-8

Showing the most recent 10 out of 55 publications